Vera Therapeutics, Inc. · NASDAQ:VERA
Vera Therapeutics — Investor Presentation (November 2026)
34 slides from Vera Therapeutics's investor presentation, November 2026
Slide 1: Corporate Presentation
Corporate Presentation November 2026 © 2026 Vera Therapeutics, Inc. Corporate Presentation
Slide 2: Forward-looking statements
Forward-looking statements Disclaimer This material has been made available to you with the consent of Vera Therapeutics, Inc. ("we", "us", "our", or the "Company"). Statements in this presentation that are not statements of historical fact are "forward-looking statements" within the meaning of the
Slide 3: Important Safety Information
Important Safety Information Indication: TRUTAKNA® (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. This indication is approved under accelerated approval based on reduction of proteinuria. It has not been
Slide 4: VERA is a San Francisco-based biotechnology company
• VERA (Nasdaq) is a San Francisco-based biotechnology company with world-class development and commercialization leadership • First commercial product: TRUTAKNA, a first-in-class BAFF and APRIL inhibitor that could transform treatment of autoimmune disease • FDA granted accelerated approval in IgAN
Slide 5: Vera pipeline
Vera pipeline Research & Discovery Preclinical Clinical Marketed IgAN TRUTAKNA pMN, FSGS, MCD Phase 2 Potential future autoimmune indications MAU868 BK virus Phase 2 Potential future VT-109 autoimmune indications Vera holds worldwide, exclusive rights to develop and commercialize TRUTAKNA, VT-109, a
Slide 6: Management team: Successful clinical and commercial track record
Management team: Successful clinical and commercial track record Marshall Fordyce, MD Nancy Boman, MD, PhD Robert Brenner, MD Lauren Frenz, MBA Founder and CEO Chief Regulatory Officer Chief Medical Officer Chief Business Officer Sean Grant, MBA David Johnson, MBA Matt Skelton Jane Wright-Mitchell C
Slide 7: Strong financial position
Strong financial position ~$459M ~72.3M Cash, cash equivalents, Shares outstanding (as of 10.29.26) and marketable securities (as of 9.30.26)1 Additional $350M non-dilutive capital available through Oxford Facility, subject to satisfaction of certain conditions 1. Pro forma unaudited estimate includ
Slide 8: Inhibition of immune complex formation in IgAN may avoid end-stage kidney disease
Inhibition of immune complex formation in IgAN may offer the potential to avoid end-stage kidney disease during a patient’s lifetime 80 71 5-Year % Mortality in US1,2 60 59 ESKD 5-year mortality comparable to cancer 40 35 20 8 0 Lung ESKD Colorectal Breast Cancer Cancer Cancer ESKD, end stage kidney
Slide 9: Atacicept: Rationally designed fusion protein
Atacicept: Rationally designed fusion protein conceived in the era of modern biotechnology IgAN is a disease of B cell origin with kidney pathology BAFF TACI eGFR stabilization, Gd-IgA1 Hematuria Proteinuria B cell potential for reduction resolution reduction kidney protection APRIL TACI receptor At
Slide 10: ORIGIN Phase 2b long-term results appear consistent with disease modification
ORIGIN Phase 2b long-term results appear consistent with disease modification Reduction in Gd-IgA1 Resolution of hematuria 0 0 Mean ± SE % Change from in % Participants (95% CI) -15 -20 Change from Baseline Baseline in Gd-IgA1 -30 -40 -45 -60 -60 -80 -75% -66% -75 -100 0 12 24 36 48 60 72 96 0 12 24
Slide 11: ORIGIN 3 trial design
ORIGIN 3 trial design Multinational, randomized, placebo-controlled trial of TRUTAKNA, self-administered at home via weekly 1-mL SC injection Double-blind treatment* Open-label extension Placebo TRUTAKNA 150 mg SC QW TRUTAKNA 150 mg SC QW Week 0 36 52 104 156 1° Endpoint met Final analysis: 2° Endpo
Slide 12: Primary endpoint: UPCR reduction
Primary endpoint: UPCR reduction Δ 42% 95% CI 29, 52 p<0.0001 10 10 Mean (95% CI) % Change from Baseline 0 0 -10 -10 -20 -20 -7% -30 -30 95% CI -19, 8 -40 -40 -50 -50 -60 -60 -46% 0 12 24 36 95% CI -53, -38 n= Week Placebo 97 96 97 95 TRUTAKNA Placebo TRUTAKNA 106 104 104 103 n=103 n=95 Interim Anal
Slide 13: TRUTAKNA was generally well tolerated in ORIGIN interim analysis
TRUTAKNA was generally well tolerated in ORIGIN 3 interim analysis TRUTAKNA Placebo Participants, % n=214 n=214 Most common adverse events (≥5%) • Most adverse events were mild or moderate in Infections 32 28 severity and resolved without treatment interruption or discontinuation Upper respiratory t
Slide 14: Vera Announces Alignment with FDA on Earlier ORIGIN Phase 3 Analysis
Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy • Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027 • Pending positive eGFR analysis, plans to submit
Slide 15: Final efficacy analysis: Patient disposition
Final efficacy analysis: Patient disposition 750 screened 319 failed screening 431 randomized 3 randomized but not dosed1 428 randomized and dosed Full analysis set and 214 TRUTAKNA 214 placebo safety analysis set 15 discontinued treatment 45 discontinued treatment 8 patient withdrawals 22 adverse e
Slide 16: Baseline demographics and characteristics
Baseline demographics and characteristics TRUTAKNA Placebo Total n=214 n=214 n=428 Age, years, median (range) 41 (18, 74) 41 (18, 70) 41 (18, 74) Male sex, n (%) 122 (57) 132 (62) 254 (59) Race, n (%) Asian 117 (55) 114 (53) 231 (54) White 94 (44) 95 (44) 189 (44) Other 3 (1) 5 (2) 8 (2) Region, n (
Slide 17: Physiologic rate of eGFR loss with TRUTAKNA vs pathologic rate with placebo
TRUTAKNA treatment resulted in a physiologic rate of eGFR loss vs pathologic rate of eGFR loss with placebo 2 Mean change from baseline1 Annualized at 52 weeks at 104 weeks eGFR slope2 Mean (95% CI) eGFR change from baseline, 0 -2 Placebo- adjusted Δ5.6 Δ11.1 Δ5.0 (3.7, 7.5) (7.7, 14.4) (3.6, 6.5) d
Slide 18: TRUTAKNA eGFR benefit observed across all prespecified subgroups
TRUTAKNA eGFR benefit observed across all prespecified subgroups Mean (95% CI) placebo-adjusted Mean (95% CI) placebo-adjusted n (%) eGFR change at 52 weeks, mL/min/1.73m2 annualized eGFR slope, mL/min/1.73m2/yr Overall 428 5.6 (3.7, 7.5) 5.0 (3.6, 6.5) <40 189 (44) 6.6 (3.6, 9.6) 6.6 (4.2, 9.0) Age
Slide 19: 76% risk reduction in composite kidney disease progression endpoint
TRUTAKNA achieved 76% risk reduction in the composite kidney disease progression endpoint TRUTAKNA Placebo Composite kidney disease progression through 104 weeks Hazard ratio Risk reduction 40 38 18% 0.24 76% (95% CI 0.12, 0.48) 30 p<0.0001 Participants, n A composite kidney disease progression even
Slide 20: TRUTAKNA reduced UPCR, Gd-IgA1, and hematuria
TRUTAKNA reduced UPCR, Gd-IgA1, and hematuria through 104 weeks UPCR reduction1 Gd-IgA1 reduction2 Hematuria resolution3 25 0 30 Change from baseline in % participants Mean (95% CI) % change from baseline Mean (95% CI) % change from baseline 15 Placebo -20 0 with hematuria (95% CI) 0 -40 -15 -25 -30
Slide 21: TRUTAKNA well tolerated with favorable safety profile
TRUTAKNA was well tolerated with a favorable safety profile, and generally comparable to placebo TRUTAKNA Placebo Participants, n (%) n=214 n=214 Adverse events 160 (75) 167 (78) • Most adverse events were mild or moderate in severity and resolved without treatment Serious adverse events1 15 (7) 33
Slide 22: ORIGIN final efficacy analysis summary
ORIGIN 3 final efficacy analysis summary • ORIGIN 3 demonstrates that TRUTAKNA has the potential for comprehensive disease modification in IgAN • TRUTAKNA treatment resulted in a physiologic rate of eGFR loss compared to a pathologic rate of eGFR loss with placebo • ORIGIN 3 met all prespecified end
Slide 23: PIONEER is evaluating atacicept in antibody mediated glomerular diseases
PIONEER is evaluating atacicept in antibody mediated glomerular diseases Primary evaluation period Optional extension period IgAN Atacicept 150 mg SC QW Adults with biopsy-proven Week 0 36 52 196 • IgAN Primary endpoint Secondary endpoint • IgAVN • recurrent IgAN post-transplant eGFR ≥20 mL/min/1.73
Slide 24: PIONEER enrolled adults with IgAN with distinct baseline characteristics
PIONEER enrolled adults with IgAN with baseline characteristics distinct from ORIGIN 3 and other Phase 3 trials Adult IgAN Post-transplant IgAN recurrence Adult IgAVN Baseline characteristic IgAN, n=101 Age, years, median (range) 41 (18-88) 5.0 Male sex, n (%) 62 (61) Typical eligibility criteria fo
Slide 25: Proteinuria reduction in PIONEER IgAN cohorts
Proteinuria reduction in PIONEER IgAN cohorts 0 UPCR eGFR IgAVN Baseline characteristic <1.0 g/g <30 Change from Baseline 24h-UPCR N, (% overall) 49 (49) 16 (16) 14 (14) Geometric Mean ± SE % -20 Age, years, median (range) 41 (18–58) 50 (24–88) 31 (19–59) Male sex, n (%) 33 (67) 11 (69) 4 (29) Asian
Slide 26: PIONEER pMN baseline characteristics
PIONEER pMN baseline characteristics Adults with pMN n=16 Age at screening, years, median (range) 57 (37–70) Male sex, n (%) 12 (75) Asian race, n (%) 0 White race, n (%) 13 (81) Hispanic/Latino ethnicity, n (%) 2 (13) Anti-PLA2R antibody, RU/mL, median (IQR) 83 (55–208) eGFR, mL/min/1.73m2, mean ±
Slide 27: Reduction in anti-PLA2R antibody and proteinuria detected as early as 4 weeks
Reduction in anti-PLA2R antibody and proteinuria are detected as early as 4 weeks Anti-PLA2R antibody reduction UPCR reduction 0 10 Anti-PLA2R % Change from Baseline UPCR % Change from Baseline 0 -20 Geometric Mean ± SE Geometric Mean ± SE -10 -40 -20 -60 -30 -80 -40 Spot UPCR 24-h UPCR -100 -50 0 4
Slide 28: Safety profile consistent with atacicept clinical development program
Safety profile consistent with the overall atacicept clinical development program IgAN pMN Participants, n (%) n=101 n=16 Adverse events 82 (81) 12 (75) • Most adverse events were mild or moderate in severity and resolved Serious adverse events 4 (4) 2 (12) without treatment interruption or Adverse
Slide 29: PIONEER interim results summary
PIONEER interim results summary • PIONEER IgAN baseline characteristics distinct from ORIGIN 3 • Preliminary results demonstrate similar reduction in UPCR at 24 weeks as ORIGIN 3 IgAN • UPCR reductions generally consistent across cohorts with: – Baseline eGFR <30 mL/min/1.73m2 – Baseline UPCR <1.0 g
Slide 30: Estimated IgAN epidemiology
Estimated IgAN epidemiology US IgAN Prevalence: ~0.04% of US Population1 + ~40K ~160K Low Risk (~24% of patients)2 + ~30K Moderate Risk (~20% of patients)2 ~90K High Risk (~56% of patients)2 Phase 3 population Phase 2 study ongoing BAFF & APRIL inhibition Patient counts rounded to nearest 1,000. 1.
Slide 31: IgAN market and TRUTAKNA hallmarks of attractive commercial opportunity
IgAN market and TRUTAKNA have many hallmarks of an attractive commercial opportunity IgAN Market TRUTAKNA • Uptake of B-cell modulators have exceeded • Strong efficacy and safety profile expectations; nephrology community expected to rapidly adopt disease-modifying therapies • Comprehensive data pac
Slide 32: Potential $10B+ U.S. market opportunity for TRUTAKNA
Potential $10B+ U.S. market opportunity for TRUTAKNA in IgAN and pipeline autoimmune diseases1 US Prevalence1 IgAN/IgAVN Sjögren’s pMN Nephrology Non-Nephrology ~500K ~700K gMG FSGS SLE MCD ITP AAV SSc LN 1. Vera Therapeutics corporate estimates for peak year market opportunity and prevalence based
Slide 33: TRUTAKNA projected catalysts
TRUTAKNA projected catalysts Catalyst 2026 2027 2028 US launch Phase 3 final efficacy analysis IgAN Projected full US approval1 Mid Planned MAA submission Q1 Planned J-NDA submission 2H IgAN Clinical results IgAN, pMN, FSGS, MCD Clinical results Vera holds worldwide, exclusive rights to develop and
Slide 34: © 2026 Vera Therapeutics, Inc. Corporate Presentation
© 2026 Vera Therapeutics, Inc. Corporate Presentation
Vera Therapeutics — Investor Presentation (November 2026) on 6ix